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Abstract
AIM: To determine the effect of Legalon-SIL (LS) on 
hepatitis C virus (HCV) core and NS5A expression and 
on heme oxygenase-1 (HMOX-1) and its transcriptional 
regulators in human hepatoma cells expressing full 
length HCV genotype 1b. 
METHODS: CON1 cells were treated with 50 μmol/L 
or 200 μmol/L LS. Cells were harvested after 2, 6 and 
24 h. HCV RNA and protein levels were determined by 
quantitative real-time polymerase chain reaction and 
Western blotting, respectively. 
RESULTS: HCV RNA (core and NS5A regions) was 
decreased after 6 h with LS 200 μmol/L (P  < 0.05). 
Both 50 and 200 μmol/L LS decreased HCV RNA lev-
els [core region (by 55% and 88%, respectively) and 
NS5A region (by 62% and 87%, respectively) after 24 h 
compared with vehicle (dimethyl sulphoxide) control (P  
< 0.01). Similarly HCV core and NS5A protein were de-
creased (by 85%, P  < 0.01 and by 65%, P  < 0.05, re-
spectively) by LS 200 μmol/L. Bach1 and HMOX-1 RNA 
were also downregulated by LS treatment (P  < 0.01), 
while Nrf2 protein was increased (P  < 0.05). 
CONCLUSION: Our results demonstrate that treat-
ment with LS downregulates HCV core and NS5A ex-
pression in CON1 cells which express full length HCV 
genotype 1b, and suggests that LS may prove to be a 
valuable alternative or adjunctive therapy for the treat-
ment of HCV infection.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Over 170 million people are infected by hepatitis C virus 
(HCV) worldwide, and of  these, approximately 85% will 
develop chronic hepatitis C (CHC). This could potentially 
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lead to fibrosis, cirrhosis, end-stage liver disease and hepa-
tocellular carcinoma[1]. The ultimate goal of  antiviral treat-
ment for hepatitis C is the sustained elimination of  HCV. 
Currently, the standard of  care for individuals with CHC is 
pegylated interferon (IFN) α-2a or IFN α-2b plus ribavirin. 
However, this protocol is far from ideal. Even under the 
best conditions of  sponsored clinical trials, sustained viro-
logic responses have been achieved in only 40%-50% of  
those with HCV genotype 1 infection[2,3]. Furthermore, seri-
ous side effects are associated with this therapy. The paucity 
of  effective and affordable treatments for HCV-infected 
patients has led scientists to seek alternative therapies. At 
present, novel therapeutic agents with various mechanisms 
of  action are under development or in clinical trials. 
Although the precise mechanisms underlying hepato-
cellular injury associated with HCV has yet to be deter-
mined, there is compelling evidence that HCV produces 
increased oxidative stress in human liver cells that is linked 
to the production of  reactive oxygen species (ROS), and 
consequent increases in cellular lipid peroxidation and 
other oxidative damage. Oxidative stress appears to be an 
important aspect of  HCV-induced hepatocellular injury[4]. 
Microsomal heme oxygenase-1 (HMOX-1) is an induc-
ible cytoprotective enzyme that catalyzes the initial and 
rate-limiting reaction in heme catabolism to release free 
iron and equimolar amounts of  carbon monoxide and 
biliverdin[5,6]. A variety of  DNA-binding proteins interact 
with regions that contain multiple antioxidant response el-
ements (ARE). Among these are nuclear factor erythroid 
2-related factor 2 (Nrf2) and Bach1, a leucine b-zipper 
transcription protein, which form heterodimers with the 
small Maf  proteins[7,8]. Nrf2 is known to be associated 
with activation of  HMOX-1 and numerous other antioxi-
dant genes in response to multiple agents[9], while Bach1 is 
a negative regulator of  HMOX-1[10].
Milk thistle (Silybum marianum) has been used since 
ancient times as a liver tonic. Silymarin (SI), a purified ex-
tract of  polyphenolic flavonoids isolated from milk thistle, 
is composed mainly of  silychristin, silydianin, silybin A, 
silybin B, isosilybin A and isosilybin B. After oral admin-
istration, the SI flavonolignans are rapidly metabolized[11]. 
Silybin (SBN) constitutes approximately 50% of  SI and 
is the most biologically active component[12]. A number 
of  studies have shown that SI has potent antioxidant 
and immunomodulatory effects in addition to numerous 
metabolic actions that may contribute to its purported 
hepatoprotective actions[13-15].
We recently showed that SI downregulates HCV RNA 
(core region) and protein in CNS3 cells that stably express 
HCV RNA core to the amino terminal of  NS3 pro-
teins[16]. Another recent study in vitro showed that SI exerts 
antiviral and antiinflammatory effects in hepatoma cell 
lines expressing the HCV full length genome of  genotype 
2a[17]. On the other hand, a randomized, double-blind, 
placebo-controlled study administering oral SI to CHC 
patients failed to show a significant effect on either serum 
aminotransferase levels or quality-of-life measures[18]. 
Legalon-SIL (LS) is a form of  SBN which is a water-
soluble formulation of  the dihydro-succinate sodium salt 
of  SBN A and SBN B in equal proportion. Recent results 
from a pilot study in patients with chronic HCV using LS 
indicate that some SI flavonolignans may have antiviral 
activity[19]. In this study we assessed the effects of  LS on 
HCV RNA and protein levels in cell lines expressing the 
full length genome of  HCV genotype 1b. We also deter-
mined the effects of  LS on HMOX-1, Bach1, and Nrf2 
expression in these cells.
MATERIALS AND METHODS
Chemicals and antibodies
LS was obtained from Rottapharm-Madaus (Italy). Di-
methyl sulphoxide (DMSO) was purchased from Thermo 
Fisher Scientific Inc (Rock ford, IL, USA). A 100 mmol/L 
LS stock solution (molecular weight = 726) was prepared 
in DMSO and filtered through a 0.2 μmol/L nylon filter. 
LS was prepared fresh just prior to use in each experi-
ment. Mouse monoclonal antibody against HCV core 
protein was purchased from Abcam (Cambridge, MA, 
USA). Mouse monoclonal antibody against HCV NS5A 
was purchased from Virogen Corporation (Watertown, 
MA, USA). Rabbit polyclonal antibody against HMOX-1 
was purchased from Stress Gene (Ann Arbor, MI, USA). 
Goat monoclonal antibody against Bach1, rabbit poly-
clonal antibody against Nrf2, and mouse anti-glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) monoclonal 
antibody were purchased from Santa Cruz Biotechnology 
Inc. (Santa Cruz, CA, USA). Enhanced chemilumines-
cence (ECL)-Plus Western blotting detection reagent was 
obtained from Amersham Biosciences (Piscataway, NJ, 
USA).
Cell cultures and treatments
Huh-7.5 and CON1 subgenomic genotype 1b HCV cell 
lines were from Apath LLC (St. Louis, MO, USA). Huh-7.5 
is a highly permissive, IFN-cured Huh-7 human hepatocel-
lular carcinoma cell line derivative. The CON1 cell line is 
a Huh-7.5 cell population containing the full-length HCV 
genotype 1b replicon.
Huh-7.5 and CON1 cells were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 
10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL 
streptomycin, and selection antibiotic for CON1 cells 
(750 μg/mL G418).
Colorimetric MTT assay
Cellular proliferation of  treated CON1 cells was assessed 
by measuring the conversion of  MTT [3-(4, 5-dimethyl-
thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] to MTT 
formazan (Sigma-Aldrich). The absorbance was measured 
on a Synergy HT microtiter plate reader (Biotek Instru-
ments, Winooski, VT, USA), at a wavelength of  570 nm 
with background subtraction at 690 nm. Decreases in 
absorption were taken as an index of  decreased cellular 
proliferation.
Propidium iodide assay
The viability of  CON1 cells treated with LS was also con-
firmed by the standard propidium iodide [(PI); Invitrogen, 
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USA)] assay. The experiment was performed according to 
the manufacturer’s recommended protocol. CON1 cells 
were plated in 12-well plates 24 h before treatment and in-
cubated at 37℃. LS was dissolved in DMSO and added to 
the cell culture medium. The effects of  LS on cell viability 
were studied at various concentrations (0, 50, 100, 200, 
300, 400 and 500) μmol/L and at different time points 
(4, 8, and 24 h). Percent cell viability was determined by 
counting cell density in drug-treated cells and in DMSO-
treated cells as control in the same incubation period [per-
centage of  cellular viability = (total cell count-PI positive 
cell count)/total cell count*100]. All experiments were 
repeated 3 times.
RNA isolation and quantitative reverse transcriptase 
polymerase chain reaction
RNA from treated cells was isolated by TRIZOL reagent 
(Invitrogen). The RNA concentration and purity were 
determined by measuring absorbance at 260/280 nm. Re-
verse transcription was performed on 1 μg of  total RNA 
to generate cDNA using the iScript cDNA Synthesis Kit 
(Bio-Rad Laboratories, Hercules, CA, USA). Quantita-
tive real time reverse transcriptase (RT)-polymerase chain 
reaction (PCR) was performed using a CFX-96 Real-Time 
PCR Detection System (Bio-Rad Laboratories) and iQTM 
SYBR Green Supermix (Bio-Rad Laboratories). Sequence 
specific primers for HMOX-1, Bach1, and GAPDH were 
designed as described[20]. Nucleotide sequences of  other 
primers are as follows: NS5A: Forward primer, 5'-CG-
GACGTAGCAGTGCTCACTTC-3' and reverse primer, 
5-'TGATGAGCTGGCCAAGGAGG-3'; Nrf2: Forward 
primer, 5'-CCTTTCTCGCCTAGGCATCA-3', reverse 
primer, 5'-CCCTTCAGCTCTCCCTACCG-3'. Fold 
change values were calculated by comparative cycle thresh-
old (Ct) value analysis after normalizing for the quantity of  
GAPDH mRNA in samples.
Protein preparation and Western blotting
Cells were grown to near confluence and washed with 
phosphate-buffered saline (PBS), lysed in a buffer contain-
ing 1% Triton X-100 with PBS and Halt Protease Inhibitor 
Cocktail (Pierce Chemicals, Rockford, IL, USA). Protein 
concentrations were measured using the bicinchoninic acid 
method. Total proteins (10 μg) were separated on 4%-12% 
gradient sodium dodecyl sulphate-polyacrylamide gel (In-
vitrogen Laboratories) and electrophoretically transferred 
onto an Immun-Blot PVDF (Invitrogen Laboratories). 
The membranes were blocked for 1 h in PBS containing 5% 
nonfat dry milk, and then incubated for 1 h with the pri-
mary antibody at room temperature. The dilutions of  the 
primary antibodies were as follows: 1:1000 for anti-HCV 
core antibody; 1:1000 for anti-HCV NS5A antibody; 1:500 
for anti-HMOX-1, and 1:1000 for anti-Bach1, anti-Nrf2, 
and anti-GAPDH antibody. After 4 washes with 0.1% 
Tween 20 in PBS (PBS-T), the membranes were incubated 
for 1 h with a secondary antibody (anti-rabbit, anti-goat or 
anti-mouse immunoglobulin G; dilution 1:10 000). Finally, 
the membranes were washed 4 times with PBS-T, and the 
bound antibodies were visualized with the ECL-Plus che-
miluminescence system. A computer based imaging sys-
tem, LAS 3000 (Fuji Film, USA) was used to measure the 
relative optical density of  each specific band obtained after 
Western blotting.
Statistical analysis
Data are expressed as mean ± SE of  the mean. Statistical 
differences between groups were analyzed by analysis of  
variance followed by Dunnett’s test. P < 0.05 was consid-
ered significant.
RESULTS
Cytotoxicity of Legalon-SIL in CON1
Appropriate doses of  LS in the cell lines were determined. 
Effects of  different doses of  LS on cell viability in CON1 
cells were assessed by PI staining (Figure 1). LS concentra-
tions of  50-300 μmol/L had no significant effect on cell 
viability, whereas concentrations equal to or more than 
400 μmol/L caused significant cytotoxicity in the cells (P 
< 0.05). Similar results were demonstrated with the MTT 
proliferation assay (data not shown). 
Legalon-SIL downregulates HCV RNA as well as HCV 
core and NS5A proteins in CON1 cells  
LS downregulated HCV RNA (core region) in a dose-de-
pendent and also a time-dependent manner in CON1 cells. 
The HCV RNA (core region) level was decreased 21% fol-
lowing 6 h treatment with LS 200 μmol/L compared with 
the DMSO control (P < 0.05, Figure 2A). HCV RNA (core 
region) levels were further decreased after 24 h treatment 
by both LS 50 μmol/L (55% decrease, P < 0.05) and 200 
μmol/L (88% decrease, P < 0.01) when compared with ve-
hicle (DMSO) control (Figure 2A). The HCV RNA (NS5A 
region) level was also decreased 43% following 6 h treat-
ment with LS 200 μmol/L compared with DMSO control 
(P < 0.01 Figure 2B), and was also further decreased after 
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Figure 1  Effects of legalon-SIL on CON1 cell viability. Cellular viability of 
CON1 cells was measured using the propidium iodide assay after 4, 8, and 
24 h of exposure to legalon-SIL (LS) at varying concentrations ranging from 
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24 h treatment by both LS 50 μmol/L (62% decrease, P 
< 0.01) and 200 μmol/L (87% decrease, P < 0.01) (Figure 
2B). LS 200 μmol/L also downregulated HCV core (by 
57%) and NS5A protein (by 49%) after 24 h of  treatment 
although this was statistically significant only for HCV 
core protein, P < 0.05). This effect was more pronounced 
following 48 h of  treatment: LS 200 μmol/L decreased 
HCV NS5A protein expression by 65% (P < 0.05), while 
LS significantly decreased HCV core protein expression in 
a dose-dependent manner (52% reduction at 50 μmol/L 
and 85% reduction at 200 μmol/L P < 0.01) (Figure 3).
Legalon-SIL downregulates HMOX-1 and Bach1 mRNA 
levels in CON1 cells while it upregulates Nrf2 protein 
expression 
HMOX-1 and Bach1 mRNA levels were significantly de-
creased following 24 h treatment by both LS 50 μmol/L 
and 200 μmol/L when compared with the DMSO control 
(HMOX-1 decreased by 40%, P < 0.01; Bach1 decreased 
by 35%, P < 0.01; Figure 4). LS treatment decreased Bach1 
protein level, although not significantly, while it significant-
ly increased Nrf2 protein expression (P < 0.05) (Figure 5).
HMOX-1 expression is increased in CON1 cells in 
comparison with its expression in the parental Huh7.5 
cell line
For investigation of  possible effects of  stable transfection 
of  the HCV genome in CON1 replicon system, we com-
pared HMOX-1, Bach1, and Nrf2 mRNA levels between 
CON1 cells and Huh7.5 cells, the ‘parental’ cell line. In un-
treated CON1 cells, the HMOX-1 mRNA level was 3-fold 
higher than in untreated Huh7.5 cells (P < 0.01), while 
there was no significant difference in the level of  Bach1 or 
Nrf2 mRNA between CON1 and Huh7.5 cells (Figure 6).
DISCUSSION
The current treatment for CHC is a combination of  pe-
gylated IFN-α and ribavirin which is effective only in 
40%-50% of  treated patients infected with genotype-1, 
by far the most frequent HCV genotype worldwide. This 
therapeutic regimen is expensive, prolonged (usually at 
least 48 wk) and causes serious side effects. Therefore in-
vestigations continue to search for alternative treatments 
for hepatitis C. SI is an herbal remedy that has been used 
to treat acute and chronic liver diseases for millennia[12-22]. 
Despite this broad use, the exact molecular mechanism by 
which SI confers hepatoprotection is yet to be elucidated. 
Ferenci et al[19] recently showed that LS, as used in our 
studies, significantly reduced serum HCV RNA level in pa-
tients who had not responded to combination therapy with 
full dose pegylated IFN and ribavirin. They showed that 
SBN was effective only when administered intravenously, 
as LS, and that the antiviral effect was dose-dependent. 
They reported that HCV RNA was undetectable in 7 (out 
of  14) patients receiving 15 and 20 mg/kg SBN as LS. 
In a recent study in vitro[23], SBN A, SBN B, a mixture of  
SBN A and SBN B, and LS were shown to inhibit HCV 
RNA-dependent RNA polymerase (RdRP) function and 
inhibited HCV genotype 1b sub-genomic replicon replica-
tion and HCV genotype 2a strain JFH1 replication in cell 
culture. Our results extend these findings showing that LS 
inhibits HCV replication in human hepatoma cells express-
ing full-length HCV genotype 1b. In this study, we also 
showed that LS doses equal to 400 μmol/L and higher are 
cytotoxic for human hepatoma cells similar to other recent 
results[23]. The exact pharmacokinetics of  SI and LS re-
main to be determined. However, it is suggested that oral 
doses of  SI up to 2.1 g/d are safe and well-tolerated[24]. In 
the present study, we showed that LS started to downregu-
late HCV RNA in a dose-dependent manner after 2 h, but 
the significant effect was observed after 6 h of  treatment. 
Although LS 200 μmol/L was found to downregulate 
HCV RNA and proteins significantly in CON1 cells, LS 
50 μmol/L was also found to be effective in downregula-
tion of  HCV RNA. 
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Figure 2  Time course of effects of legalon-SIL on hepatitis C virus RNA in CON1 cells. CON1 cells were grown to near confluence and the medium was changed to 5% 
fetal bovine serum (FBS) plus Dulbecco’s modified Eagle’s medium, then treated with vehicle only (DMSO) or 50 or 200 μmol/L legalon-SIL (LS). The cells were harvested 
after 2, 6, and 24 h after treatment. The levels of hepatitis C virus (HCV) RNA [core region (A) and NS5A region (B)] were quantified using qRT-PCR as described in “Materials 
and Methods”. The amounts of HCV RNA were normalized to glyceraldehyde-3-phosphate dehydrogenase. A: LS 50 μmol/L downregulated HCV RNA (core region) after 
24 h. LS 200 μmol/L downregulated HCV RNA (core region) after 6 and 24 h; B: LS 50 μmol/L downregulated HCV RNA (NS5A region) after 24 h. LS 200 μM downregu-
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In addition to a direct effect of  LS on HCV replication, 
for instance inhibition of  RdRP, LS might downregulate 
HCV through interaction with signaling molecules or other 
as yet unknown host factors. For example, Polyak et al[25] 
reported that SI suppresses TNF-α activation of  nuclear 
factor-κB-dependent transcription, without affecting bind-
ing of  p50 and p65 to DNA. They also reported that all 
SI-related compounds which they studied blocked JFH-1 
virus-induced oxidative stress, including compounds that 
lacked antiviral activity. 
In the present study, we found that LS decreased HM-
OX-1 mRNA in CON1 cells as well as the mRNA level 
of  Bach1, which is its transcriptional repressor. However, 
no effect was observed on HMOX-1 and Bach1 protein 
levels, despite modest upregulation of  Nrf2 protein. Bach1 
and Nrf2 compete for binding to the ARE and exert their 
Bach1-induced repressive, or Nrf2-induced activating ef-
fects on HMOX-1 transcription. It is noteworthy to men-
tion that for Nrf2 to bind to ARE, Bach1 needs to be dis-
located from the binding sites[26]. Therefore, a lower level 
of  Bach1 is necessary for the maximal effect of  Nrf2 on 
HMOX-1 transcription. As our study did not show down-
regulation of  Bach1 protein, it is possible to hypothesize 
that Bach1 does not dissociate from ARE to allow Nrf2 to 
bind. Therefore HMOX-1 is not upregulated despite mod-
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Figure 4  Effects of legalon-SIL on heme oxygenase-1, Bach1, and nuclear fac-
tor erythroid 2-related factor 2 mRNA levels after 24 h. CON1 cells were grown 
to near confluence and medium was changed to 5% FBS plus Dulbecco’s modified 
Eagle’s medium, then treated with vehicle only (DMSO) or 50 or 200 μmol/L legalon-
SIL (LS). The cells were harvested 24 h after treatment. The levels of HMOX-1, 
Bach1, and nuclear factor erythroid 2-related factor 2 (Nrf2) mRNA were quantified 
using quantitative reverse transcriptase polymerase chain reaction as described in 
“Materials and Methods”. The amounts of HMOX-1, Bach1, and Nrf2 mRNA were 
normalized to glyceraldehyde-3-phosphate dehydrogenase. Data are presented as 
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Figure 3  Effects of legalon-SIL on hepatitis C virus core and NS5A protein levels in CON1 cells after 24 and 48 h. CON1 cells were grown to near confluence 
and the medium was changed to 5% FBS plus Dulbecco’s modified Eagle’s medium, then treated with vehicle only (DMSO) or 50 or 200 μmol/L legalon-SIL (LS). The 
cells were harvested 24-48 h after treatment. Total protein (10 μg) was separated on 4%-12% gradient sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
and electrophoretically transferred onto an Immun-Blot PVDF. Hepatitis C virus core and NS5A protein levels were assessed through Western blotting. Representative 
Western blots, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-normalized quantifications are shown after 24 h (A, B), and 48 h (C, D). Data for protein 




































est elevation of  Nrf2 protein. Additionally, other HMOX-1 
transcriptional factors may be affected by LS  (e.g. changes 
in Keap1 or Kelch, glutathione, other thiol-containing 
compounds, levels of  heme, other metalloporphyrins, etc.) 
which were not all examined in this study[27]. 
Oxidative stress plays an important role in various 
diseases, including viral infection and chronic inflamma-
tion. HCV gene expression, in particular HCV RNA (core 
region) expression, can increase the levels of  ROS[28], and 
therefore upregulate HMOX-1[20,29]. We also compared 
HMOX-1 mRNA levels between CON1 cells and its pa-
rental cell line (Huh7.5), and we identified a 3-fold upregu-
lation of  HMOX-1 in the HCV replicon system compared 
with the parental cell line. Although SBN is a well-known 
antioxidant and cytoprotective enzyme, and upregulation of  
Nrf2 protein could be attributed to this antioxidant effect 
of  LS, lack of  HMOX-1 upregulation could be explained 
by anti-HCV activity of  LS. Since HMOX-1 is already 
increased by HCV infection in CON1 cells, its level is de-
creased toward normal levels as LS attenuates HCV infec-
tion. This downregulatory effect of  LS on HMOX-1 seems 
to be more pronounced at the RNA level, and is compen-
sated by an Nrf2 increase at the protein level.
In conclusion, LS downregulates HCV in hepatoma 
cell lines expressing full length HCV genotype 1b. LS treat-
ment is also associated with downregulation of  HMOX-1 
mRNA and upregulation of  Nrf2 protein. Further research 
is needed to further delineate mechanisms of  the LS effect 
on HCV replication and on CHC.
COMMENTS
Background
Chronic hepatitis C virus (HCV) infection is a global health problem, and one 
causal factor for development of liver cirrhosis and hepatocellular carcinoma. The 
current therapy for HCV is interferon (IFN) α-2a or IFNα-2b plus ribavirin which is 
effective in only 40%-50% of those with HCV genotype 1 infection. Furthermore, 
serious side effects are associated with this therapy. The paucity of effective 
and affordable treatments for HCV-infected patients has led scientists to seek 
alternative therapies.
Research frontiers
Silymarin, also known as milk thistle extract, inhibits HCV infection and also displays 
antioxidant, antiinflammatory, and immunomodulatory actions that contribute to its 
hepatoprotective effects. In this study the authors demonstrated that Legalon-SIL 
(LS), a water-soluble formulation of silybin A and silybin B downregulates expression 
of HCV mRNA and protein in replicon CON1 cells which are human hepatoma cell 
lines stably transfected with full-length HCV genotype 1b.
Innovations and breakthroughs
This report highlighted that LS decreases HCV core and NS5A expression. 
Additionally, the authors demonstrated that LS modulates expression of heme 
oxygenase-1 and its transcriptional regulators, Bach1 and Nrf2. This is the first 
study examining the effects of LS using a human hepatoma cell line expressing 
full-length HCV genotype 1b. 
Applications 
Our results suggest that LS may prove to be a valuable alternative or adjunctive 
therapy for the treatment of HCV infection.
Terminology
LS is a form of SBN which is a water-soluble formulation of the dihydro-
succinate sodium salt of silybin A and silybin B in equal proportions. 
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Figure 5  Effects of legalon-SIL on HMOX-1, Bach1, and Nrf2 protein levels in CON1 cells after 48 h. CON1 cells were grown to near confluence and the medium 
was changed to 5% FBS plus Dulbecco’s modified Eagle’s medium, and then treated with vehicle only (DMSO) or 50 or 200 μmol/L legalon-SIL (LS). The cells were 
harvested 48 h after treatment. Total protein (10 μg) was separated on 4%-12% gradient sodium dodecyl sulphate-polyacrylamide gel electrophoresis and electropho-
retically transferred onto an Immun-Blot PVDF. HMOX-1, Bach1, and Nrf2 protein levels were assessed through Western blotting, and normalized to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). A: Representative Western blottings. B: Results of these independent experiments quantified and normalized to GAPDH. Data 
for protein levels are mean ± SE (n = 3 independent experiments). aP < 0.05 vs DMSO control.
Figure 6  HMOX-1, Bach1, and Nrf2 mRNA levels in CON1 vs Huh 7.5 cells. 
The levels of HMOX-1, Bach1, and Nrf2 mRNA in untreated Huh 7.5 and CON1 
cells were quantified using quantitative reverse transcriptase polymerase chain 
reaction as described in “Materials and Methods”. The amounts of HMOX-1, 
Bach1 and Nrf2 mRNA were normalized to GAPDH. Data for mRNA levels are 
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Peer review
The paper will appeal to clinicians as well as researchers involved in the field of 
elucidating the mechanisms of silymarin in HCV positive patients.
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